N -Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues

ACS Chemical Neuroscience

Volumn 6, Issue 7, 2015, Pages 1165-1175

  Nichols, David E ^a   Sassano, M Flori ^a   Halberstadt, Adam L ^b   Klein, Landon M ^b   Brandt, Simon D ^c   Elliott, Simon P ^d   Fiedler, Wolfgang J ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^d Inverness Medical Innovations   (United States)

^e NONE   (Germany)

Author keywords

5 HT2 receptors; 5 HT2A; 5 methoxytryptamine; agonist; mouse head twitch; phenethylamine; Serotonin

Indexed keywords

5 METHOXYTRYPTAMINE; BENZYL DERIVATIVE; CALCIUM; PARTIAL AGONIST; PHENETHYLAMINE DERIVATIVE; SEROTONIN 2 AGONIST; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; TRYPTAMINE; N-BENZYL-5-METHOXYTRYPTAMINE; SEROTONIN 2 ANTAGONIST; TRYPTAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; EFFECTIVE CONCENTRATION; HEAD TWITCH; HUMAN; HUMAN CELL; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; HEAD MOVEMENT; METABOLISM; PHYSIOLOGY;

RATTUS;

5-METHOXYTRYPTAMINE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD MOVEMENTS; HUMANS; MALE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; PHENETHYLAMINES; RATS; RECEPTORS, SEROTONIN; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; TRYPTAMINES;

EID: 84937038387     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500292d     Document Type: Article

References (45)

1. Lawn, W., Barratt, M., Williams, M., Horne, A., and Winstock, A. (2014) The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample J. Psychopharmacol. 28, 780-788
2. Poklis, J. L., Devers, K. G., Arbefeville, E. F., Pearson, J. M., Houston, E., and Poklis, A. (2014) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death Forensic Sci. Int. 234, e14-e20
3. Walterscheid, J. P., Phillips, G. T., Lopez, A. E., Gonsoulin, M. L., Chen, H. H., and Sanchez, L. A. (2014) Pathological findings in 2 cases of fatal 25I-NBOMe toxicity Am. J. Forensic Med. Pathol. 35, 20-25
4. Nikolaou, P., Papoutsis, I., Stefanidou, M., Spiliopoulou, C., and Athanaselis, S. (2015) 2C-I-NBOMe, an "N-bomb"that kills with "Smiles". Toxicological and legislative aspects Drug Chem.Toxicol. 38, 113-119
5. European Monitoring Centre for Drugs and Drug Addiction (2014) Risk Assessment Report of a New Psychoactive Substance: 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), EMCDDA, Lisbon, Portugal.
6. World Health Organization (2014) Thirty-Sixth Meeting of the Expert Committee on Drug Dependence, World Health Organization, Geneva, Switzerland.
7. Council of the European Union (2014) 2014/688/EU: Council implementing decision of 25 December 2014 on subjecting '4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures Off. J. Eur. Union L287, 22
8. Shulgin, A. T. (1978) Psychotomimetic Drugs: Structure-Activity Relationships, in Handbook of Psychopharmacology, Chapter 6, pp 243-333, Plenum Press, New York.
9. Shulgin, A. and Shulgin, A. (1991) PIHKAL: A Chemical Love Story, Transform Press, Berkeley, CA.
10. Heim, R., Pertz, H. H., and Elz, S. (1999) Preparation and in vitro pharmacology of novel secondary amine-type 5-HT2A receptor agonists: from submillimolar to subnanomolar activity Arch. Pharm. Pharm. Med. Chem. 332, 34
11. Elz, S., Klass, T. H. R., Wamke, U., and Pertz, H. H. (2002) Development of highly potent partial agonists and chiral antagonists as tools fo the study of 5-HT2A-receptor mediated functions Naunyn-Schmiedebergs Arch. Pharmacol. 365 (Suppl 1) R29
12. Heim, R. (2003) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur Entwicklung eines neuen Struktur-Wirkungskonzepts, Ph.D. Thesis, Freie Universität Berlin, Berlin, Germany.
13. Braden, M. R., Parrish, J. C., Naylor, J. C., and Nichols, D. E. (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists Mol. Pharmacol. 70, 1956-1964
14. Heim, R. and Elz, S. (2000) Novel extremely potent partial 5-HT2A receptor agonists: successful application of a new structure-activity concept Arch. Pharm. Pharm. Med. Chem. 333, 39
15. 2A agonists WIREs Membr. Transp. Signaling 1, 559-579
16. Braden, M. R. (2007) Towards a Biophysical Understanding of Hallucinogen Action, Ph.D. Thesis, Purdue University, West Lafayette, IN.
17. Silva, M. E., Heim, R., Strasser, A., Elz, S., and Dove, S. (2011) Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor J. Comput.-Aided Mol. Des. 25, 51-66
18. Glennon, R. A., Dukat, M., el Bermawy, M., Law, H., De Los Angeles, J., Teitler, M., King, A., and Herrick-Davis, K. (1994) Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines J. Med. Chem. 37, 1929-1935
19. Takagi, K., Takayanagi, I., Irikura, T., Nishino, K., and Ito, M. (1969) A potent competitive inhibitor of 5-hydroxytryptamine: 3-(2′-benzylaminoethyl)-5-methoxyindol hydrochloride Jpn. J. Pharmacol. 19, 234-239
20. Leff, P., Martin, G. R., and Morse, J. M. (1986) The classification of peripheral 5-HT2-like receptors using tryptamine agonist and antagonist analogues Br. J. Pharmacol. 89, 493-499
21. 2A Receptor and the Isolation of Aeruginascin from the Hallucinogenic Mushroom Inocybe aeruginascens, Ph.D. Thesis, Georg-August-Universität zu Göttingen, Göttingen, Germany.
22. Halberstadt, A. L. and Geyer, M. A. (2013) Characterization of the head-twitch response induced by hallucinogens in mice: Detection of the behavior based on the dynamics of head movement Psychopharmacology 227, 727-739
23. Hansen, M. (2010) Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain, Ph.D. Thesis, University of Copenhagen, Copenhagen, Denmark.
24. Casale, J. F. and Hays, P. A. (2012) Characterization of eleven 2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) derivatives and differentiation from their 3- and 4-methoxybenzyl analogues-Part I Microgram J. 9, 84-109
25. Abdel-Magid, A. F., Carson, K. G., Harrris, B. D., Maryanoff, C. A., and Shah, R. D. (1996) Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures J. Org. Chem. 61, 3849-3862
26. Dougherty, J. P. and Aloyo, V. J. (2011) Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice Psychopharmacology 215, 581-593
27. Braden, M. R. and Nichols, D. E. (2007) Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor Mol. Pharmacol. 72, 1200-1209
28. Johnson, M. P., Loncharich, R. J., Baez, M., and Nelson, D. L. (1994) Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines Mol. Pharmacol. 45, 277-286
29. Johnson, M. P., Audia, J. E., Nissen, J. S., and Nelson, D. L. (1993) N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-HT2 receptor Eur. J. Pharmacol. 239, 111-118
30. Halberstadt, A. L. and Geyer, M. A. (2014) Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response Neuropharmacology 77, 200-207
31. Fantegrossi, W. E., Harrington, A. W., Eckler, J. R., Arshad, S., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., and Woods, J. H. (2005) Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats Psychopharmacology 181, 496-503
32. Fantegrossi, W. E., Harrington, A. W., Kiessel, C. L., Eckler, J. R., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., and Woods, J. H. (2006) Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats Pharmacol., Biochem. Behav. 83, 122-129
33. Fantegrossi, W. E., Simoneau, J., Cohen, M. S., Zimmerman, S. M., Henson, C. M., Rice, K. C., and Woods, J. H. (2010) Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice J. Pharmacol. Exp. Ther. 335, 728-734
34. Fantegrossi, W. E., Gray, B. W., Bailey, J. M., Smith, D. A., Hansen, M., Kristensen, J. L., and Woods, J. H. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT receptors, in mice. Psychopharmacology (Berl). 2014, not provided
35. Bedard, P. and Pycock, C. J. (1977) Wet-dog shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity Neuropharmacology 16, 663-670
36. Matthews, W. D. and Smith, C. D. (1980) Pharmacological profile of a model for central serotonin receptor activation Life Sci. 26, 1397-1403
37. Benneyworth, M. A., Xiang, Z., Smith, R. L., Garcia, E. E., Conn, P. J., and Sanders-Bush, E. (2007) A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis Mol. Pharmacol. 72, 477-484
38. Canal, C. E., Olaghere da Silva, U. B., Gresch, P. J., Watt, E. E., Sanders-Bush, E., and Airey, D. C. (2010) The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen Psychopharmacology 209, 163-174
39. Halberstadt, A. L., Koedood, L., Powell, S. B., and Geyer, M. A. (2011) Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice J. Psychopharmacol. 25, 1548-1561
40. Corne, S. J. and Pickering, R. W. (1967) A possible correlation between drug-induced hallucinations in man and a behavioural response in mice Psychopharmacologia 11, 65-78
41. Darmani, N. A., Martin, B. R., and Glennon, R. A. (1990) Withdrawal from chronic treatment with (±)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice Eur. J. Pharmacol. 186, 115-118
42. Leth-Petersen, S., Bundgaard, C., Hansen, M., Carnerup, M. A., Kehler, J., and Kristensen, J. L. (2014) Correlating the metabolic stability of psychedelic 5-HT agonists with anecdotal reports of human oral bioavailability Neurochem. Res. 39, 2018-2023
43. Juncosa, J. I., Jr., Hansen, M., Bonner, L. A., Cueva, J. P., Maglathlin, R., McCorvy, J. D., Marona-Lewicka, D., Lill, M. A., and Nichols, D. E. (2013) Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands ACS Chem. Neurosci. 4, 96-109
44. Hansen, M., Phonekeo, K., Paine, J. S., Leth-Petersen, S., Begtrup, M., Brauner-Osborne, H., and Kristensen, J. L. (2014) Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists ACS Chem. Neurosci. 5, 243-249
45. Braun, U., Shulgin, A. T., Braun, G., and Sargent, T., III. (1977) Synthesis and body distribution of several iodine-131 labeled centrally acting drugs J. Med. Chem. 20, 1543-1546